SCHEMBL5864655

SCHEMBL5864655

COc1cc2ncnc(Nc3c(F)c(F)c(Br)c(F)c3F)c2cc1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 11/20 0.63
RET P07949 7/20 0.63
KIF5B P33176 7/20 0.63
EGFR P00533 11/20 0.62
FLT1 P17948 2/20 0.58
MKNK1 Q9BUB5 2/20 0.58
JAK3 P52333 1/20 0.58
KDM4E B2RXH2 1/20 0.57
GAK O14976 1/20 0.57
MAPK13 O15264 1/20 0.57
ABL1 P00519 1/20 0.57
ERBB2 P04626 1/20 0.57
CYP1A2 P05177 1/20 0.57
CDK1 P06493 1/20 0.57
CYP3A4 P08684 1/20 0.57
FBP1 P09467 1/20 0.57
CYP2D6 P10635 1/20 0.57
MAPT P10636 1/20 0.57
CYP2C9 P11712 1/20 0.57
SRC P12931 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7962820 0.84 KDR (0.73) KDRRETKIF5BEGFRFLT1
Hydrochloric Acid SCHEMBL7215101 0.83 KDR (0.72) KDRRETKIF5BEGFRFLT1
SCHEMBL5864737 0.81 EGFR (0.78) KDRRETKIF5BEGFRFLT1
SCHEMBL5864645 0.80 EGFR (0.67) KDRRETKIF5BEGFRFLT1
SCHEMBL5864522 0.80 EGFR (0.74) KDRRETKIF5BEGFRFLT1
SCHEMBL31554485 0.79 EGFR (0.64) KDRRETKIF5BEGFRFLT1
Hydrochloric Acid SCHEMBL7209985 0.78 KDR (0.70) KDRRETKIF5BEGFRFLT1
SCHEMBL16760438 0.78 RET (1.00) KDRRETKIF5BEGFRFLT1
SCHEMBL5864525 0.77 KDR (1.00) KDRRETKIF5BEGFRFLT1
SCHEMBL5467825 0.77 EGFR (1.00) KDRRETEGFRFLT1MKNK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040039002-A1 6,7-Dimethoxyquinazolines and therapeutic use thereof PARKER HUGHES INSTITUTE 2004-02-26 US claimed
JP-2002540103-A 2002-11-26 JP claimed
US-20020137757-A1 Quinazolines and therapeutic use thereof PARKER HUGHES INSTITUTE (US) 2002-09-26 US claimed
US-20020111360-A1 Quinazoline formulations and therapeutic use thereof PARKER HUGHES INSTITUTE 2002-08-15 US claimed
US-6358962-B2 ANTIALLERGENS; ANTITUMOR AGENTS; ANTICANCER AGENTS PARKER HUGHES INSTITUTE 2002-03-19 US claimed
EP-1163228-A1 QUINAZOLINES AND THERAPEUTIC USE THEREOF Parker Hughes Institute (US) 2001-12-19 EP claimed
US-20010016588-A1 Quinazolines and therapeutic use thereof HUGHES INSTITUTE (US) 2001-08-23 US claimed
US-6258820-B1 ANTITUMOR AGENTS PARKER HUGHES INSTITUTE 2001-07-10 US claimed
WO-2000056720-A1 QUINAZOLINES AND THERAPEUTIC USE THEREOF PARKER HUGHES INSTITUTE (US) 2000-09-28 WO claimed
US-7038049-B2 Haloanilino quinazolines and therapeutic use thereof PARKER HUGHES INSTITUTE (US) 2006-05-02 US disclosed
US-20050075353-A1 Quinazolines and therapeutic use thereof PARKER HUGHES INSTITUTE (US) 2005-04-07 US disclosed
US-20040039002-A1 6,7-Dimethoxyquinazolines and therapeutic use thereof PARKER HUGHES INSTITUTE 2004-02-26 US disclosed
US-6638939-B2 Anticancer agents PARKER HUGHES INSTITUTE 2003-10-28 US disclosed
US-20020137757-A1 Quinazolines and therapeutic use thereof PARKER HUGHES INSTITUTE (US) 2002-09-26 US disclosed
EP-1163228-A1 QUINAZOLINES AND THERAPEUTIC USE THEREOF Parker Hughes Institute (US) 2001-12-19 EP disclosed
EP-1162974-A1 QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF Parker Hughes Institute (US) 2001-12-19 EP disclosed
US-20010016588-A1 Quinazolines and therapeutic use thereof HUGHES INSTITUTE (US) 2001-08-23 US disclosed
US-6258820-B1 ANTITUMOR AGENTS PARKER HUGHES INSTITUTE 2001-07-10 US disclosed
WO-2000056338-A1 QUINAZOLINE FORMULATIONS AND THERAPEUTIC USE THEREOF PARKER HUGHES INSTITUTE (US) 2000-09-28 WO disclosed
WO-2000056720-A1 QUINAZOLINES AND THERAPEUTIC USE THEREOF PARKER HUGHES INSTITUTE (US) 2000-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075353-A1 Quinazolines and therapeutic use thereof HRH2, HRH4, HNMT KDR 3004/4885RET 1370/4885KIF5B 3899/4885
US-20020111360-A1 Quinazoline formulations and therapeutic use thereof CMA1, MAST3, MAST1 KDR 2810/4885RET 2800/4885KIF5B 3284/4885
US-20020137757-A1 Quinazolines and therapeutic use thereof HRH2, HRH4, HNMT KDR 3004/4885RET 1370/4885KIF5B 3899/4885
US-20040039002-A1 6,7-Dimethoxyquinazolines and therapeutic use thereof HRH2, HNMT, HRH4 KDR 2273/4885RET 1115/4885KIF5B 3041/4885
US-20010016588-A1 Quinazolines and therapeutic use thereof HRH2, HRH4, HNMT KDR 3004/4885RET 1370/4885KIF5B 3899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.